An MDMA analogue which could end up in direct competition with Emyria's own ones. Very strange.All to generate some professional fees. Emeryia has changed so much from a promising biotech to a clinical service provider.
DUR Duratec snags $76.5M in works from Woodside and Defence respectively - including spy network upgrade
